• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2020 年 2 月至 10 月期间丹麦的 SARS-CoV-2 感染动态:过去疫情的性质及其未来可能的发展。

SARS-CoV-2 infection dynamics in Denmark, February through October 2020: Nature of the past epidemic and how it may develop in the future.

机构信息

Center for Fundamental Living Technology (FLinT) Department for Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark.

Santa Fe Institute, Santa Fe, New Mexico, United States of America.

出版信息

PLoS One. 2021 Apr 9;16(4):e0249733. doi: 10.1371/journal.pone.0249733. eCollection 2021.

DOI:10.1371/journal.pone.0249733
PMID:33836034
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8034750/
Abstract

BACKGROUND

Initially, the relative sizes of the asymptomatic and the symptomatic infected populations were not known for the COVID-19 pandemic and neither was the actual fatality rate. Therefore it was not clear either how the pandemic would impact the healthcare system. As a result it was initially predicted that the COVID-19 epidemic in Denmark would overwhelm the healthcare system and thus both the diagnosis and treatment of other hospital patients were compromised for an extended period.

AIM

To develop a mathematical model, which includes both asymptomatic and symptomatic infected persons, for early estimation of the epidemic's course, its Infection Fatality Rate and the healthcare system load in Denmark, both retrospectively and prospectively.

METHODS

The SEIRS (Susceptible-Exposed-Infected-Recovered-Susceptible) model including deaths outside hospitals and separate assessments of symptomatic and asymptomatic cases (based on seroprevalence) with different immunological memories. Optimal model parameters are in part identified by Monte Carlo based Least Square Error methods while micro-outbreaks are modeled by noise and explored in Monte Carlo simulations. Estimates for infected population sizes are obtained by using a quasi steady state method.

RESULTS

The calculations and simulations made by the model were shown to fit with the observed development of the COVID-19 epidemic in Denmark. The antibody prevalence in the general population in May 2020 was 1.37%, which yields a relative frequency of symptomatic and asymptomatic cases of 1 to 5.2. Due to the large asymptomatic population, the Infection Mortality Rate was only 0.4%. However, with no non-pharmacological restrictions the COVID-19 death toll was calculated to have more than doubled the national average yearly deaths within a year. The transmission rate ℜ0 was 5.4 in the initial free epidemic period, 0.4 in the lock-down period and 0.8-1.0 in the successive re-opening periods through August 2020. The large asymptomatic population made the termination of the epidemic difficult and micro-outbreaks occurred when the country re-opened. The estimated infected population size July 15 to August 15 was 2,100 and 12,200 for October 1-20, 2020.

CONCLUSIONS

The results of the model show, that COVID-19 has a low Infection Fatality Rate because the majority of infected persons are either asymptomatic or with few symptoms. A minority of the infected persons, therefore, requires hospitalization. That means that for a given infection pressure of both symptomatic and asymptomatic infected there will be a lower pressure on the capacity of the health care system than previously predicted. Further the epidemic will be difficult to terminate since about 84% of the infected individuals are asymptomatic but still contagious. The model may be useful if a major infection wave occurs in the autumn-winter season as it could make robust estimates both for the scale of an ongoing expanding epidemic and for the expected load on the healthcare system. The simulation may also be useful to evaluate different testing strategies based on estimated infected population sizes. The model can be adjusted and scaled to other regions and countries, which is illustrated with Spain and USA.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/fcbff2a3c059/pone.0249733.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/c53720735672/pone.0249733.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/570cc83e5d29/pone.0249733.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/2473259777b5/pone.0249733.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/554f58d25b77/pone.0249733.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/ccbf9e373335/pone.0249733.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/a57bb1ff1942/pone.0249733.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/df9cd5cb635c/pone.0249733.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/b5457da0336b/pone.0249733.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/c187006cc7d1/pone.0249733.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/96cfaf86420b/pone.0249733.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/fcbff2a3c059/pone.0249733.g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/c53720735672/pone.0249733.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/570cc83e5d29/pone.0249733.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/2473259777b5/pone.0249733.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/554f58d25b77/pone.0249733.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/ccbf9e373335/pone.0249733.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/a57bb1ff1942/pone.0249733.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/df9cd5cb635c/pone.0249733.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/b5457da0336b/pone.0249733.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/c187006cc7d1/pone.0249733.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/96cfaf86420b/pone.0249733.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9462/8034750/fcbff2a3c059/pone.0249733.g011.jpg
摘要

背景

最初,对于 COVID-19 大流行,我们并不知道无症状和有症状感染者的相对规模,也不知道实际死亡率。因此,我们也不清楚大流行将如何影响医疗保健系统。因此,最初预测 COVID-19 疫情在丹麦将使医疗保健系统不堪重负,从而在很长一段时间内影响对其他住院患者的诊断和治疗。

目的

开发一种数学模型,该模型包括无症状和有症状感染者,用于早期估计丹麦的疫情进程、其感染死亡率和医疗保健系统负荷,包括回顾性和前瞻性估计。

方法

SEIRS(易感-暴露-感染-恢复-易感)模型包括医院外死亡,并对基于血清流行率的有症状和无症状病例(基于血清流行率)进行单独评估,具有不同的免疫记忆。通过基于蒙特卡罗的最小二乘误差方法部分确定最佳模型参数,而微爆发则通过噪声建模,并在蒙特卡罗模拟中进行探索。通过准稳态方法获得感染人群规模的估计。

结果

模型的计算和模拟结果表明,它与丹麦 COVID-19 疫情的实际发展情况相符。2020 年 5 月,普通人群中的抗体流行率为 1.37%,这意味着有症状和无症状病例的相对频率为 1 比 5.2。由于无症状人群庞大,感染死亡率仅为 0.4%。然而,由于没有非药物限制,COVID-19 的死亡人数预计将在一年内超过全国平均年死亡人数的两倍。在最初的自由流行期间,传播率 ℜ0 为 5.4,封锁期间为 0.4,2020 年 8 月至 8 月连续重新开放期间为 0.8-1.0。大量的无症状人群使疫情难以结束,当该国重新开放时会发生微爆发。2020 年 7 月 15 日至 8 月 15 日和 10 月 1 日至 20 日的估计感染人群规模分别为 2100 和 12200。

结论

模型结果表明,COVID-19 的感染死亡率较低,因为大多数感染者要么无症状,要么症状很少。因此,少数感染者需要住院治疗。这意味着,对于有症状和无症状感染者的给定感染压力,医疗保健系统的压力将低于先前的预测。此外,由于大约 84%的感染者无症状但仍具有传染性,因此疫情将难以结束。如果秋季-冬季出现大规模感染浪潮,该模型可能会很有用,因为它可以对正在进行的不断扩大的疫情规模以及对医疗保健系统的预期负荷进行强有力的估计。该模拟还可以用于评估基于估计的感染人群规模的不同测试策略。该模型可以调整和扩展到其他地区和国家,西班牙和美国的情况就是如此。

相似文献

1
SARS-CoV-2 infection dynamics in Denmark, February through October 2020: Nature of the past epidemic and how it may develop in the future.2020 年 2 月至 10 月期间丹麦的 SARS-CoV-2 感染动态:过去疫情的性质及其未来可能的发展。
PLoS One. 2021 Apr 9;16(4):e0249733. doi: 10.1371/journal.pone.0249733. eCollection 2021.
2
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益(CoV-Surv 研究):一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
3
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
4
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.在 2020 年春季大流行期间估计 SARS-CoV-2 在纽约市的感染病死率:基于模型的分析。
Lancet Infect Dis. 2021 Feb;21(2):203-212. doi: 10.1016/S1473-3099(20)30769-6. Epub 2020 Oct 19.
5
Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.重建未被确认的 COVID-19 病例和感染的早期全球动态。
BMC Med. 2020 Oct 22;18(1):332. doi: 10.1186/s12916-020-01790-9.
6
First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate.智利圣地亚哥的 2019 冠状病毒病(SARS-CoV-2)首例疫情:血清流行率、无症状感染和感染病死率。
Epidemics. 2022 Sep;40:100606. doi: 10.1016/j.epidem.2022.100606. Epub 2022 Jul 13.
7
Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.估算疫情早期 SARS-CoV-2 的死亡率:在中国湖北和欧洲六个地区的建模研究。
PLoS Med. 2020 Jul 28;17(7):e1003189. doi: 10.1371/journal.pmed.1003189. eCollection 2020 Jul.
8
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
9
Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study.丹麦 SARS-CoV-2 抗体的流行情况:全国范围内的基于人群的血清流行病学研究。
Eur J Epidemiol. 2021 Jul;36(7):715-725. doi: 10.1007/s10654-021-00796-8. Epub 2021 Aug 22.
10
Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission.对医护人员进行 SARS-CoV-2 筛查突出了无症状携带在 COVID-19 传播中的作用。
Elife. 2020 May 11;9:e58728. doi: 10.7554/eLife.58728.

引用本文的文献

1
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?从新冠疫情管理中可以吸取哪些教训?
Int J Public Health. 2025 May 30;70:1607727. doi: 10.3389/ijph.2025.1607727. eCollection 2025.
2
Epidemiological outcomes and policy implementation in the Nordic countries during the COVID-19 pandemic.新冠疫情期间北欧国家的流行病学结果及政策实施情况。
Arch Public Health. 2025 Feb 20;83(1):46. doi: 10.1186/s13690-025-01531-5.
3
Mathematical Modeling of SARS-CoV-2 Transmission between Minks and Humans Considering New Variants and Mink Culling.

本文引用的文献

1
Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study.香港一项全港队列研究:2019冠状病毒病(COVID-19)的病死率显著低于严重急性呼吸综合征(SARS)
Clin Infect Dis. 2021 May 18;72(10):e466-e475. doi: 10.1093/cid/ciaa1187.
2
Humoral Immune Response to SARS-CoV-2 in Iceland.冰岛人针对 SARS-CoV-2 的体液免疫反应。
N Engl J Med. 2020 Oct 29;383(18):1724-1734. doi: 10.1056/NEJMoa2026116. Epub 2020 Sep 1.
3
The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results?
考虑新变种和水貂扑杀的新冠病毒在水貂与人类之间传播的数学模型
Trop Med Infect Dis. 2023 Aug 3;8(8):398. doi: 10.3390/tropicalmed8080398.
4
Citizens' economic recovery models for a pandemic.应对疫情的公民经济复苏模式。
PLoS One. 2023 Feb 3;18(2):e0266531. doi: 10.1371/journal.pone.0266531. eCollection 2023.
5
Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020.华盛顿州西雅图市2019年10月至2020年4月期间新冠病毒2型抗体血清流行率
PLoS One. 2021 May 27;16(5):e0252235. doi: 10.1371/journal.pone.0252235. eCollection 2021.
2019新型冠状病毒肺炎中皮质类固醇的合理使用:能否取得理想效果?
J Infect. 2021 Jan;82(1):e6-e7. doi: 10.1016/j.jinf.2020.08.001. Epub 2020 Aug 5.
4
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19).2019年早期急性冠状病毒病(COVID-19)儿童和成人上呼吸道中的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒载量
Clin Infect Dis. 2021 Jul 1;73(1):148-150. doi: 10.1093/cid/ciaa1157.
5
Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave.在疫情高峰期间,米兰最大儿童医院的医护人员中新冠病毒感染的血清阳性率较低。
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1468-1469. doi: 10.1017/ice.2020.401. Epub 2020 Aug 6.
6
Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.随着时间的推移,医疗护理(包括抗感染药物的使用)对 COVID-19 住院患者预后的影响。
Int J Antimicrob Agents. 2020 Oct;56(4):106129. doi: 10.1016/j.ijantimicag.2020.106129. Epub 2020 Aug 2.
7
Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后中和抗体反应的纵向动力学。
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539. doi: 10.1093/cid/ciaa1143.
8
High intensities of population movement were associated with high incidence of COVID-19 during the pandemic.人口流动强度大与大流行期间 COVID-19 的高发病率有关。
Epidemiol Infect. 2020 Aug 3;148:e177. doi: 10.1017/S0950268820001703.
9
The implications of silent transmission for the control of COVID-19 outbreaks.静默传播对控制 COVID-19 疫情的影响。
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515. doi: 10.1073/pnas.2008373117. Epub 2020 Jul 6.
10
Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient.COVID-19 患者的 SARS-CoV-2 抗体纵向特征和中和活性。
J Infect. 2020 Sep;81(3):e31-e32. doi: 10.1016/j.jinf.2020.06.076. Epub 2020 Jul 2.